GIANT BIOGENE HOLDING CO., LTD (Stock code: 2367) announced that its wholly-owned subsidiary, Shaanxi Giant Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate (Registration Certificate No.: Guo Xie Zhu Zhun 20253132049) from China National Medical Products Administration for a product titled Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers. The product is designed for filling facial dermal tissue to correct frontal dynamic wrinkles, including glabellar lines, forehead lines, and crow’s feet.

According to the announcement dated 23 October 2025, this is China’s first recombinant type I native-sequence collagen facial injectable product, approved through a joint review by both the Medical Device Evaluation and Pharmaceutical Evaluation divisions. The new approval underscores the company’s R&D and industrialization capabilities and expands its product lineup in the skin rejuvenation market. Plans are in place to gradually introduce the product to market and work closely with existing brands and distribution channels.

Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the company.